Factory 99% Ruxolitinib Powder CAS 941678-49-5 Anti-Inflammatory Ruxolitinib

• Customization: Available
• Powder: Yes
• Customized: Customized
• Model NO.: A266
• Certification: GMP, HSE, ISO 9001, USP, BP
• Suitable for: Elderly, Children, Adult
• State: Powder
• Purity: >99%
• Name: Ruxolitinib
• CAS: 941678-49-5
• Appearance: White Powder
• Assay: 99%
• OEM: Available
• Sample: Available
• Suitable: Adult
• MOQ: 100g
• Function: Anti-Inflammatory
• Transport Package: Foil Bag
• Specification: 99
• Trademark: /
• Origin: China
• Production Capacity: 10000 Kgs Per Month

Product Description

Product Name	Ruxolitinib
Appearance	White Powder
CAS NO.	941678-49-5
Molecular Formula	C17H18N6·H3PO4
Storage	Keep in a cool, dry, dark location

 

Ruxolitinib is an oral, small-molecule inhibitor of Janus kinases (JAKs), specifically JAK1 and JAK2. It is a potent and selective agent that targets these kinases, which are known to play a crucial role in various inflammatory and proliferative diseases.

 

 

1. Treatment of Myelofibrosis: Ruxolitinib is primarily used for the treatment of patients with myelofibrosis, a chronic bone marrow disorder characterized by fibrosis and abnormal blood cell production.
2. Management of Polycythemia Vera: It is also indicated for the management of polycythemia vera, a rare blood disorder where the bone marrow produces too many red blood cells.
3. Other Hematological Disorders: Ruxolitinib has shown promise in the treatment of other hematological disorders, including post-polycythemia vera myelofibrosis and post-essential thrombocythemia myelofibrosis, as well as in the management of corticosteroid-refractory acute graft-versus-host disease.

1. Inhibition of JAK Signaling: By inhibiting JAK1 and JAK2, ruxolitinib blocks the JAK-STAT signaling pathway, which is implicated in the pathogenesis of myelofibrosis and other hematological disorders. This inhibition reduces the production of inflammatory cytokines and growth factors, thereby modulating the abnormal immune and inflammatory responses associated with these diseases.
2. Reduction of Splenomegaly and Symptom Burden: In clinical trials, ruxolitinib has been shown to effectively reduce splenomegaly (enlarged spleen) and improve symptoms such as fatigue, anemia, and bone pain in patients with myelofibrosis.
3. Improvement of Survival and Quality of Life: By targeting the underlying disease mechanisms and alleviating symptoms, ruxolitinib has the potential to improve survival and quality of life for patients with myelofibrosis and other indicated hematological disorders.